Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lux receives US FDA complete response letter for uveitis drug

This article was originally published in Scrip

Executive Summary

Lux Biosciences has received a complete response letter from the US FDA for Luveniq (oral voclosporin, LX211; licensed from Isotechnika Pharma), its treatment candidate for non-infectious uveitis. It requested that an additional clinical trial is conducted in order for an approval to be considered. Lux said it would conduct an additional pivotal study of Luveniq, which it expects to begin before the end of the year.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts